Zusammenfassung
Nicht nur bei der Entstehung der koronaren Herzerkrankung
(KHK), sondern insbesondere beim akuten Koronarsyndrom (ACS) spielen
Thrombozyten eine zentrale Rolle. Der zugrundeliegenden Plaqueruptur
beim ACS folgt eine durch Thrombozyten getriggerte überschießende
Reaktion des Organismus mit dem Ziel, die entstandene „Wunde” zu
verschließen. Für die Therapie gilt deshalb, die
Aktivität der Thrombozyten zu reduzieren. Etabliert ist
dabei die Acetylsalicylsäure (ASS), die sich in der Akutsituation
und in der Sekundärprophylaxe von koronaren Ereignissen
bewährt hat. Im Zeitalter der perkutanen Interventionen
war dies jedoch nicht ausreichend. Erst die duale Hemmung der Thrombozytenaggregation
mit Thienopyridinen, wie zunächst Ticlopidin, später
Clopidogrel in Kombination mit ASS, erbrachte den Durchbruch nicht
nur in der Prophylaxe von Stentthrombosen, sondern verbesserte die
Prognose beim ACS.
Der vorliegende Beitrag gibt eine Übersicht über die
aktuellen Entwicklungen auf dem Gebiet der Thienopyridine. Der Schwerpunkt
liegt in der Evidenz-basierten Nutzenbewertung von Prasugrel bzw.
Prasugrel im Vergleich zu Clopidogrel in der klinischen Praxis.
Abstract
Platelet activation plays a pivotal role in the pathogenesis
of coronary artery disease. The long-term benefit of dual anti-platelet
therapy with clopidogrel and aspirin is well established for patients
with acute coronary syndrome and for secondary prophylaxis of coronary
artery disease. This review discusses latest developments in the field
of the thienopyridines. Particularly, we focus on the evidence-based
use of prasugrel or prasugrel versus clopidogrel in clinical practice.
Schlüsselwörter
Prasugrel - Clopidogrel - Thienopyridine - akutes Koronarsyndrom
Keywords
prasugrel - clopidogrel - thienopyridines - acute coronary syndrome
Literatur
1
Angiolillo D J, Guzman L A.
Clinical
overview of promising nonthienopyridine antiplatelet agents.
Am
Heart J.
2008;
156
S23-28
2
Baurand A, Eckly A, Bari N. et
al .
Desensitization of the platelet aggregation response
to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
Thromb Haemost.
2000;
84
484-491
3
Brandt J T, Close S L, Iturria S J. et al .
Common polymorphisms of CYP2C19
and CYP2C9 affect the pharmacokinetic and pharmacodynamic response
to clopidogrel but not prasugrel.
J Thromb Haemost.
2007;
5
2429-2436
4
Brass L F, Manning D R, Cichowski K, Abrams C S.
Signaling through
G proteins in platelets: to the integrins and beyond.
Thromb
Haemost.
1997;
78
581-589
5
Braun O O, Johnell M, Varenhorst C. et al .
Greater reduction of platelet activation
markers and platelet-monocyte aggregates by prasugrel compared to
clopidogrel in stable coronary artery disease.
Thromb Haemost.
2008;
100
626-633
6
Farid N A, Payne C D, Small D S. et al .
Cytochrome P450 3A inhibition
by ketoconazole affects prasugrel and clopidogrel pharmacokinetics
and pharmacodynamics differently.
Clin Pharmacol Ther.
2007;
81
735-741
7
Fuster V, Badimon L, Badimon J J, Chesebro J H.
The pathogenesis
of coronary artery disease and the acute coronary syndromes (2).
N Engl J Med.
1992;
326
310-318
8
Gachet C.
Identification, characterization, and inhibition of the platelet
ADP receptors.
Int J Hematol.
2001;
74
375-381
9
Hechler B, Eckly A, Ohlmann P. et
al .
The P2Y1 receptor, necessary but not sufficient
to support full ADP-induced platelet aggregation, is not the target
of the drug clopidogrel.
Br J Haematol.
1998;
103
858-866
10
Jakubowski J A, Winters K J, Naganuma H, Wallentin L.
Prasugrel: a novel
thienopyridine antiplatelet agent. A review of preclinical and clinical
studies and the mechanistic basis for its distinct antiplatelet profile.
Cardiovasc Drug Rev.
2007;
25
357-374
11
Jantzen H M, Gousset L, Bhaskar V. et al .
Evidence for two distinct G-protein-coupled
ADP receptors mediating platelet activation.
Thromb Haemost.
1999;
81
111-117
12
Mega J L, Close S L, Wiviott S D. et al .
Cytochrome p-450 polymorphisms and
response to clopidogrel.
N Engl J Med.
2009;
360
354-362
13
Mega J L, Close S L, Wiviott S D, Shen L. et al .
Cytochrome P450 genetic polymorphisms and the response to prasugrel:
relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Circulation.
2009;
119
2553-2560
14
Mehta S R, Yusuf S.
The Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) trial programme; rationale,
design and baseline characteristics including a meta-analysis of
the effects of thienopyridines in vascular disease.
Eur
Heart J.
2000;
21
2033-2041
15
Mehta S R, Yusuf S, Peters R J. et al .
Effects of pretreatment with clopidogrel
and aspirin followed by long-term therapy in patients undergoing
percutaneous coronary intervention: the PCI-CURE study.
Lancet.
2001;
358
527-533
16
Quinn M J, Fitzgerald D J.
Ticlopidine
and clopidogrel.
Circulation.
1999;
100
1667-1672
17
Steinhubl S R, Berger P B, Mann J T. et al .
Early and sustained dual
oral antiplatelet therapy following percutaneous coronary intervention: a
randomized controlled trial.
JAMA.
2002;
288
2411-2420
18
Sugidachi A, Ogawa T, Kurihara A. et al .
The greater in vivo antiplatelet effects
of prasugrel as compared to clopidogrel reflect more efficient generation
of its active metabolite with similar antiplatelet activity to that
of clopidogrel’s active metabolite.
J Thromb
Haemost.
2007;
5
1545-1551
19
Wallentin L, Becker R C, Budaj A. et al .
Ticagrelor versus clopidogrel in patients
with acute coronary syndromes.
N Engl J Med.
2009;
361
1045-1057
20
Wiviott S D, Antman E M, Winters K J. et al .
Randomized comparison of prasugrel
(CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with
clopidogrel in percutaneous coronary intervention: results of the
Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI
26 trial.
Circulation.
2005;
111
3366-3373
21
Wiviott S D, Braunwald E, Angiolillo D J. et al .
Greater clinical benefit
of more intensive oral antiplatelet therapy with prasugrel in patients
with diabetes mellitus in the trial to assess improvement in therapeutic
outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis
in Myocardial Infarction 38.
Circulation.
2008;
118
1626-1636
22
Wiviott S D, Braunwald E, McCabe C H. et al .
Intensive oral antiplatelet therapy for
reduction of ischaemic events including stent thrombosis in patients
with acute coronary syndromes treated with percutaneous coronary
intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis
of a randomised trial.
Lancet.
2008;
371
1353-1363
23
Wiviott S D, Braunwald E, McCabe C H. et al .
Prasugrel versus clopidogrel in patients
with acute coronary syndromes.
N Engl J Med.
2007;
357
2001-2015
24
Wiviott S D, Trenk D, Frelinger A L. et al .
Prasugrel compared with high loading- and
maintenance-dose clopidogrel in patients with planned percutaneous
coronary intervention: the Prasugrel in Comparison to Clopidogrel
for Inhibition of Platelet Activation and Aggregation-Thrombolysis
in Myocardial Infarction 44 trial.
Circulation.
2007;
116
2923-2932
25
Yusuf S, Zhao F, Mehta S R. et al .
Effects of clopidogrel in addition to aspirin in
patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med.
2001;
345
494-502
Dr. Natig Gassanov
Herzzentrum Köln Klinik III für
Innere Medizin
Kerpener Str. 62
50924 Köln
Phone: 0221/47832544
Email: Natig.Gassanov@uk-koeln.de